HWM
EGRX

HighMark Wealth Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

HighMark Wealth Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,200
Closed -$8.21K – 632
2024
Q3 		$8.21K Buy
+2,200
New +$10.5K ﹤0.01% 327

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

HighMark Wealth Management's EGRX Position: Q4 2024 in Review

HighMark Wealth Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 2,200 shares — an estimated $8.21K sold.

HighMark Wealth Management first reported a position in EGRX in Q3 2024 and held it in 1 quarter. The position peaked at $8.21K in Q3 2024. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • HighMark Wealth Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • HighMark Wealth Management sold 2,200 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $8.21K.
  • HighMark Wealth Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2024 and held it in 1 quarter.
  • HighMark Wealth Management's Eagle Pharmaceuticals, Inc. position peaked at $8.21K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on HighMark Wealth Management's 13F filing for Q4 2024, filed 31 Jan 2025.